>...
数据说明

1. 本数据库收录了clinical trials官网的全量数据,并保持每天与官网同步更新。
2. 本数据库支持多维度数据筛选,如NCT号、介入方式、申办者、协作者、临床阶段、适应症等多个字段检索。
3. 将试验组药物与药渡数据库中药物做了人工关联,支持药物中文名称、商品名以及各种药物别名检索筛选。

关闭
临床列表
NCT筛选   共295423条数据
更新日期:2019-05-20
  • NCT号
  • 主要研究者
  • 临床阶段
    • N/A
    • Phase Ⅰ/Ⅱ
    • Phase Ⅲ
    • Phase Ⅱ/Ⅲ
    • Phase Ⅰ
    • Phase Ⅳ
    • Phase Ⅱ
  • 介入方式
  • 国家/地区
  • 试验状态
    • Active not recruiting
    • Recruiting
    • Approved for marketing
    • Suspended
    • Completed
    • Enrolling by invitation
    • Withdrawn
    • Terminated
    • Not yet recruiting
  • 申办者/协作者
  • 适应症
  • 最后更新日期 -
其他选项:
中国CDE注册与受理 NDA ANDA BLA 上一页 下一页
首页 上一页 1 2 下一页 末页 GO
  • NCT号
  • 介入方式
  • 适应症
  • 临床阶段
  • 试验状态
  • 最后更新日期
  • NCT03953898

  • Drug: Olaparib

  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; IDH1 NP_005887.2:p.R132C; IDH1 NP_005887.2:p.R132G; IDH1 NP_005887.2:p.R132H; IDH1 NP_005887.2:p.R132L; IDH1 NP_005887.2:p.R132S; IDH2 NP_002159.2:p.R140X; IDH2 NP_002159.2:p.R172G; IDH2 NP_002159.2:p.R172K; IDH2 NP_002159.2:p.R172M; IDH2 NP_002159.2:p.R172W; Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; Therapy-Related Acute Myeloid Leukemia

  • Phase Ⅱ

  • Not yet recruiting

  • May 16, 2019

  • NCT03954990

  • Drug: Metronidazole Oral; Drug: Placebo Oral Tablet

  • Bacterial Vaginoses

  • Phase Ⅰ

  • Not yet recruiting

  • May 16, 2019

  • NCT03955133

  • Other: Adverse Drug Reaction ADRe Profile for Polypharmacy

  • Polypharmacy

  • N/A

  • Active not recruiting

  • May 16, 2019

  • NCT03954600

  • Drug: NPT520-34 (125 mg); Drug: Placebos (125 mg)

  • Healthy Volunteers

  • Phase Ⅰ

  • Recruiting

  • May 16, 2019

  • NCT03954834

  • Drug: Tirzepatide; Drug: Placebo

  • Type 2 Diabetes Mellitus

  • Phase Ⅲ

  • Not yet recruiting

  • May 16, 2019

  • NCT03954639

  • Drug: EXPAREL 13.3Mg/mL Suspension for Injection; Drug: Bupivacaine Hydrochloride

  • Bunion; Metatarsophalangeal Fusion; Midfoot Fusion; Hindfoot Fusion; Total Ankle Arthroplasty; Forefoot Surgery

  • Phase Ⅲ

  • Not yet recruiting

  • May 16, 2019

  • NCT03467360

  • Drug: acetazolamide in combination with platinum and etoposide-based radiochemotherapy

  • Small Cell Lung Cancer

  • Phase Ⅰ

  • Not yet recruiting

  • May 16, 2019

  • NCT03954626

  • Biological: brolucuzumab 6 mg IVT

  • Age-Related Macular Degeneration; Macular Degeneration; Wet Macular Degeneration; Retinal Degeneration; Retinal Diseases; Eye Diseases

  • Phase Ⅲ

  • Not yet recruiting

  • May 16, 2019

  • NCT03955146

  • Drug: Pamrevlumab; Drug: Placebo

  • Idiopathic Pulmonary Fibrosis

  • Phase Ⅲ

  • Not yet recruiting

  • May 16, 2019

  • NCT03184584

  • Drug: PBI-4050

  • Alström Syndrome

  • Phase Ⅱ/Ⅲ

  • Active not recruiting

  • May 16, 2019

  • NCT03349554

  • Other: body-scan meditation; Diagnostic Test: Psychological evaluation

  • Parkinson's Disease

  • N/A

  • Completed

  • May 16, 2019

  • NCT03955042

  • Drug: Pemetrexed

  • Chordoma

  • Phase Ⅰ

  • Not yet recruiting

  • May 16, 2019

  • NCT03954444

  • Drug: Oxymetazoline Hydrochloride; Drug: Rhofade Cream, 1%; Drug: Placebo

  • Rosacea

  • Phase Ⅲ

  • Recruiting

  • May 16, 2019

  • NCT03954327

  • Drug: Emtricitabine (FTC)/Tenofovir Disoproxil (TDF); Drug: Raltegravir; Drug: Placebo Oral Capsule [CEBOCAP]

  • Primary Biliary Cholangitis

  • Phase Ⅱ

  • Not yet recruiting

  • May 16, 2019

  • NCT03954067

  • Biological: ASP9801

  • Metastatic Cancer; Solid Tumors; Advanced Cancer

  • Phase Ⅰ

  • Not yet recruiting

  • May 16, 2019

  • NCT03952572

  • Drug: Cyclophosphamide; Drug: pegylated liposomal doxorubicin; Drug: Vincristine; Drug: Prednisone; Drug: Doxorubicin

  • Peripheral T-cell Lymphoma

  • Phase Ⅲ

  • Recruiting

  • May 15, 2019

  • NCT03953001

  • Device: Adminstration Technique using Buzzy external distractor; Drug: 2% Lidocaine with 1:50,000 epinephrine; Drug: Topical Anesthetic

  • Local Anaesthetic; Dental Anxiety

  • N/A

  • Completed

  • May 15, 2019

  • NCT03953196

  • Biological: Imvanex; Biological: Shingrix; Biological: LPS; Biological: Candin

  • Healthy

  • Recruiting

  • May 15, 2019

  • NCT03953092

  • Drug: YG1699; Drug: Placebo

  • Diabete Type 2

  • Phase Ⅰ

  • Recruiting

  • May 15, 2019

  • NCT03952923

  • Biological: CD19-CAR-T cells

  • B-cell Malignancy

  • Phase Ⅰ

  • Not yet recruiting

  • May 15, 2019